v3.25.2
Business Combinations - Narrative (Details)
$ in Thousands, $ in Millions
12 Months Ended
Feb. 07, 2024
AUD ($)
shares
Feb. 07, 2024
CAD ($)
Mar. 31, 2025
CAD ($)
Mar. 31, 2024
CAD ($)
Feb. 07, 2024
CAD ($)
shares
Feb. 06, 2024
Disclosure of detailed information about business combination [line items]            
Measurement period adjustments     $ 400      
Revenue of acquiree since acquisition date       $ 2,800    
Loss of acquiree since acquisition date       900    
Revenue as if combination occurred at beginning of period       44,400    
Profit as if combination occurred at beginning of period       $ 6,100    
MedReleaf Australia            
Disclosure of detailed information about business combination [line items]            
Ownership interest prior to the acquisition           9.57%
MedReleaf Australia            
Disclosure of detailed information about business combination [line items]            
Percentage of voting equity interests acquired 90.43%       90.43%  
Total purchase price for remaining interest $ 51.0       $ 44,341  
Cash consideration $ 9.5       $ 8,249  
Common shares issued (in shares) | shares 6,948,994       6,948,994  
Common shares issued $ 41.6       $ 36,092  
Gain on remeasuring ownership interest in acquiree held before business combination to fair value 5.4 $ 4,700        
Cash consideration held in escrow $ 0.9       $ 800  
Common shares issued held in escrow (in shares) | shares 676,579       676,579  
Common shares issued held in escrow $ 4.0       $ 3,600  
Maximum indemnification period 1 year 1 year        
Certain tax and superannuation claims expiration period 5 years 5 years        
Transaction costs expensed   $ 2,200